

OUR NEW UNIVERSAL APPROACH TO EXPANDED CARRIER SCREENING (CS) USING EXOME SEQUENCING

	CGT Plus	CGT Mirror		CGT Sequential	
	Patient and partner using their own gametes, donors, or intended parents completing carrier screening before donor selection	Intended parents who have chosen a donor and want to mirror the donor screen or when carrier screening panel of a bank is known		Reproductive partners (including intended parents) who wish to be tested only for the genes that the other partner is positive for	
Features	Igenomix Expanded Panel including ACMG Tier 3 genes	Choose from a list of common gene panels		Use results of patient or donor carrier screening report to screen only for positive genes in the reproductive partner	
Genes	Female:539; Male: 474 (includes 65 X-linked)	Varies		1-10 single genes (+ 65 X-linked in females)	
Matching	Included Automatic	Included Requested through portal		Included Requested through portal	
Upgrades	Available through subsequent data analysis. No new sample required. Fees apply	Available through subsequent data analysis. No new sample required. Included within same test type. Fees apply if changing test type		Available through subsequent data analysis. No new sample required. Fees apply	
Genetic Counseling	Access to live or recorded pre-test webinar				
	Included for at-risk match				
	Fee applies for low-risk match and/or individual carrier status review				
Support	At-risk reproductive couples receive 15% off future PGT-M testing with Igenomix				
Sample	Blood or saliva				
TAT	20 business days - 30 calendar days				



Why choose our exome-based carrier screening?



CLINICAL ADVANTAGE

- Allows for testing of all known recessive conditions.
- Increases the overall detection rate, minimizing the global residual risk.



MATCHING

- Maximizes IVF applications, matching possible with ALL genetic lab tests in the market.
- Simplifies competitor CS panel mirroring as no resequencing is required to provide matching information.



UPGRADES

 Possibility to upgrade to include additional genes at a later date.



REANALYSIS


- Exome sequencing offers added value for future analysis of a given patient.
- Provides analytical possibilities in the adverse event of a newborn with a genetic condition.



Available for domestic and international patients and donors.



CGT is an advanced genetic test performed before pregnancy that determines the risk of having a child with a genetic condition.



The American College of Obstetricians and Gynecologists (ACOG) makes the following recommendation:



Information about genetic carrier screening should be provided to every pregnant woman.

Archibald et al: 2018

THE MOST COMMON MONOGENIC DISORDERS DETECTED WITH THE CGT TEST ARE:	PROPORTION OF CARRIERS
Cystic fibrosis	1 in 25
Spinal muscular atrophy	1 in 50
Autosomal recessive polycystic kidney disease	1 in 70

GLOBAL PREVALENCE IN LIVE BIRTHS OF DOWN SYNDROME VS MONOGENIC DISEASES				
1 in 800 live births	1 in 100 live births			
Down Syndrome	Monogenic Diseases			